GATC Health’s Stem Cell Therapy for Diabetes

GATC Health's Stem Cell Therapy for Diabetes

GATC Health Corp. announced a groundbreaking stem cell therapy for diabetes, detailed in a recent publication in the American Journal of Biomedical Science & Research. This autologous therapy uses a patient’s own stem cells to potentially treat both Type 1 and Type 2 diabetes, offering improved blood sugar control and reduced medication dependence. The process is […]

Adia Nutrition Enters Global Stem Cell Market – New Clinic in Winter Park, FL

Adia Nutrition Enters Global Stem Cell Market

Adia Nutrition, a publicly traded company, has opened a Florida clinic, Adia Med, offering stem cell treatments using ethically sourced umbilical cord stem cells. This clinic aims to provide convenient and FDA-compliant stem cell therapies, comparable to international clinics, for various conditions. The company highlights the quality of its stem cells, the convenience of a […]

NYSCF and Janssen Partner on Neurodegenerative Disease Drug Discovery

NYSCF and Janssen Partner on Neurodegenerative Disease Drug Discovery

The New York Stem Cell Foundation Research Institute (NYSCF) and Janssen Research & Development, a Johnson & Johnson company, have partnered to accelerate the development of precision medicines for neurodegenerative diseases.  NYSCF’s AI-powered platform, using automated stem cell systems, will be leveraged to identify new drug targets and therapies. This collaboration combines NYSCF’s expertise in stem cell […]

BioCentriq Expands Cell Therapy Manufacturing

BioCentriq Expands Cell Therapy Manufacturing

This exciting news in the cell therapy sector could revolutionize how quickly life-changing therapies reach patients. BioCentriq, a leading cell therapy contract development and manufacturing organization (CDMO), is set to expand its operations and establish a cutting-edge cell therapy manufacturing facility in Princeton, New Jersey. This facility will become BioCentriq’s new headquarters, marking a significant […]

Promising Phase 1 Results for Hemophilia A Gene Therapy

Promising Phase 1 Results for Hemophilia A Gene Therapy

Expression Therapeutics announced promising Phase 1 clinical trial results for its novel gene therapy, ET3, treating hemophilia A. The trial, detailed in the New England Journal of Medicine, showed significant increases in Factor VIII levels and a reduction in bleeding events in participants with severe hemophilia A. The therapy uses a lentiviral vector targeting hematopoietic stem […]

FDA Grants Breakthrough Therapy Designation to Seres’ SER-155

FDA Grants Breakthrough Therapy Designation to Seres' SER-155-thumbnail

Seres Therapeutics announced that the FDA granted Breakthrough Therapy designation to SER-155, their lead investigational drug, for reducing bloodstream infections in adults undergoing stem cell transplants. This designation is based on positive Phase 1b clinical trial data showing a significant reduction in infections compared to a placebo. A meeting with the FDA to discuss the […]

Eterna Therapeutics Investigates ERNA-101 in Cancer Models

Eterna Therapeutics Investigates ERNA-101 in Cancer Models

Eterna Therapeutics, a preclinical-stage company, announced a research collaboration with MD Anderson Cancer Center to evaluate its lead induced mesenchymal stem cell therapy, ERNA-101, for treating ovarian and breast cancers.  ERNA-101, a proprietary allogenic cell therapy, aims to stimulate antitumor immunity. The research will assess ERNA-101’s effects both in vitro and in vivo, with potential future studies exploring […]

FDA Approves StemCyte’s REGENECYTE™ Cord Blood Therapy

FDA Approves StemCyte's REGENECYTE Cord Blood Therapy

StemCyte Inc. announced FDA approval of its REGENECYTE™ cord blood stem cell therapy for treating blood and immune system disorders, making them the first U.S.-based biotech company to receive such a biologics license for this therapy in 2024. REGENECYTE™ is an allogeneic therapy derived from umbilical cord blood. The company is also exploring other applications […]

BioRestorative Therapies Expands Stem Cell Research with New York State License

BioRestorative Therapies Expands Stem Cell Research with New York State License

In a significant advancement for regenerative medicine, BioRestorative Therapies, Inc. has secured a provisional license from the New York State Department of Health (NYSDOH) to process allogeneic (non-autologous) donor tissue material, including stem cells, for medical research. This expansion builds upon their previous authorization, which was limited to autologous (self-donated) mesenchymal stem cells. This new […]